Veracyte Stock Price, News & Analysis

Veracyte (Nasdaq: VCYT) reported Q3 2025 results with total revenue of $131.9M (up 14%) and testing revenue of $127.8M (up 17%). Testing volume rose 19% to 43,679 tests; total volume rose 18% to 45,888 tests. GAAP net income was $19.1M (15% of revenue) and adjusted EBITDA was $39.7M or 30.1% of revenue. Cash, cash equivalents and short-term investments totaled $366.4M at quarter end, with cash from operations of $44.8M in the quarter.

The company raised full-year 2025 guidance to testing revenue $484M–$487M and total revenue $506M–$510M, and raised adjusted EBITDA margin guidance to over 25%. Key product and clinical milestones and launches were also highlighted.

Veracyte (NASDAQ: VCYT) announced two publications (Nov 3, 2025) showing research use of the Afirma GRID whole-transcriptome tool to derive mRNA signatures that may preoperatively stratify thyroid nodule cancer risk.

Key findings: researchers analyzed 445 Afirma GSC-tested samples and screened 30 molecular signatures; an "invasion signature" associated with a 30% greater likelihood of intermediate/high-risk cancer, while a "NIS expression" signature predicted low-risk cancers. Authors say further validation is required before clinical use.

Veracyte (Nasdaq: VCYT) will release its third quarter 2025 financial results after market close on Tuesday, November 4, 2025.

Management will host a conference call and live webcast to discuss results and provide a business update at 4:30 p.m. Eastern Time the same day. The live webcast link is https://edge.media-server.com/mmc/p/kcexjtb4. A replay will be available on the investor site at https://investor.veracyte.com/events-presentations. Dial-in access requires registration via the company’s investor portal.

Veracyte (NASDAQ:VCYT) announced groundbreaking results from the BALANCE trial, validating that their PAM50 molecular biomarker can predict hormone therapy effectiveness in recurrent prostate cancer patients. The study, presented at ASTRO 2025, demonstrated that among 127 patients with luminal B tumors, 72% taking apalutamide with salvage radiation therapy avoided biochemical failure, compared to 54% in the placebo group.

The prospective validation trial involved 295 men with non-metastatic prostate cancer following prostate removal surgery. The PAM50 biomarker, available through Veracyte's Decipher GRID platform, represents the first predictive biomarker validated in a prospective, randomized trial for non-metastatic prostate cancer, marking a significant advancement in personalized treatment approaches.

This breakthrough enables more precise selection of patients who would benefit from hormone therapy, potentially helping others avoid unnecessary treatment and side effects. The study results are part of 9 Decipher-focused abstracts being presented at the conference.

Veracyte (NASDAQ:VCYT) announced that groundbreaking data validating a molecular signature for predicting hormone therapy effectiveness in recurrent prostate cancer patients will be presented at ASTRO 2025. The research, conducted using Veracyte's Decipher GRID tool, is part of nine Decipher-focused abstracts to be presented at the conference.

The presentations include a significant double-blinded placebo-controlled biomarker trial of Apalutamide and radiotherapy, along with an analysis of adverse molecular features across over 200,000 patients. The conference will be held from September 27 to October 1 at the Moscone Center in San Francisco.

Veracyte (NASDAQ:VCYT) announced that 12 Afirma-related abstracts will be presented at the 2025 American Thyroid Association Annual Meeting in Scottsdale, Arizona from September 10-14. The research presentations leverage the company's Afirma Genomic Resource for Intelligent Discovery (GRID), which represents the world's largest molecular database for thyroid nodules.

The presentations include studies on cell-surface targets in thyroid tumors, mRNA expression signatures for predicting histopathology, molecular profiling comparisons between Black and White patients, and genomic landscape analysis of thyroid nodules in elderly patients. These studies stem from Veracyte's extensive database of thyroid-nodule whole-transcriptome-derived genomic profiles, which the company makes available to eligible researchers.

Veracyte (NASDAQ:VCYT) announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a fireside chat on September 9, 2025, at 4:50 p.m. Eastern Time. Investors can access a live audio webcast of the presentation through Veracyte's investor relations website, with the replay remaining available for 90 days following the event.

Veracyte (NASDAQ:VCYT) announced groundbreaking results from the Phase 3 STAMPEDE trial, published in Cell, demonstrating that their Decipher Prostate Genomic Classifier can predict chemotherapy effectiveness in metastatic prostate cancer patients.

The study of 1,523 patients revealed that those with higher Decipher scores showed improved survival benefit from docetaxel treatment (HR 0.64), while those with lower scores did not benefit significantly (HR 0.96). The trial followed patients for a median of 14 years.

Veracyte launched the expanded Decipher test for metastatic prostate cancer in June 2025, addressing an urgent need as prostate cancer causes nearly 400,000 deaths globally and is the second-leading cause of cancer deaths among U.S. men, with 315,000 new diagnoses expected this year.

Veracyte (NASDAQ:VCYT) has completed enrollment for its NIGHTINGALE clinical utility trial, evaluating the Percepta Nasal Swab test for lung cancer detection. The trial has successfully enrolled 2,400 patients across 90+ centers in the United States.

The prospective, randomized, blinded trial will follow patients for up to two years to assess the test's ability to reduce unnecessary procedures for benign nodules and accelerate treatment for cancerous ones. The Percepta Nasal Swab test has demonstrated strong clinical validation results, showing 97% sensitivity with 40% specificity for low-risk nodules and 92% specificity with 57% sensitivity for high-risk nodules.